Development of Antibody-like Proteins Targeting the Oncogenic Ser/Thr Protein Phosphatase PPM1D

Megumi Ikeura; Hiroto Tashiro; Yuka Yamagata; Hikaru Saito; Tamaki Kobayashi; Masataka Mizunuma; Kazuki Yamazaki; Keisuke Baba; Kazuhiro Furukawa; Yoshiro Chuman

Development of Antibody-like Proteins Targeting the Oncogenic Ser/Thr Protein Phosphatase PPM1D

Megumi Ikeura; Hiroto Tashiro; Yuka Yamagata; Hikaru Saito; Tamaki Kobayashi; Masataka Mizunuma; Kazuki Yamazaki; Keisuke Baba; Kazuhiro Furukawa; Yoshiro Chuman

PPM1D, a protein Ser/Thr phosphatase, is overexpressed in various cancers and functions as an oncogenic protein by inactivating the p53 pathway. Therefore, molecules that bind PPM1D are expected to be useful anti-cancer agents. In this study, we constructed a phage display library based on the antibody-like small molecule protein adnectin and screened for PPM1D-specific binding molecules. We identified two adnectins, PMDB-1 and PMD-24, that bind PPM1D specific B-loop and PPM1D430 as targets, respectively. Specificity analyses of these recombinant proteins using other Ser/Thr protein phosphatases showed that these molecules bind to only PPM1D. Expression of PMDB-1 in breast cancer-derived MCF-7 cells overexpressing endogenous PPM1D stabilized p53, indicating that PMDB-1 functions as an inhibitor of PPM1D. Furthermore, MTT assay exhibited that MCF-7 cells expressing PMDB-1 showed inhibition of cell proliferation. These data suggest that the adnectin PMDB-1 identified in this study can be used as a lead compound for anti-cancer drugs targeting intracellular PPM1D.

Показать больше [+]